Simcere Pharmaceutical Group Dirección

Dirección controles de criterios 1/4

El CEO de Simcere Pharmaceutical Group's es Jinsheng Ren , nombrado en Mar 1995, tiene una permanencia de 29.08 años. compensación anual total es CN¥2.89M, compuesta por 70.7% salario y 29.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 4.83% de las acciones de la empresa, por valor de HK$650.96M. La antigüedad media del equipo directivo y de la junta directiva es de 2 años y 4.4 años, respectivamente.

Información clave

Jinsheng Ren

Chief Executive Officer (CEO)

CN¥7.4m

Compensación total

Porcentaje del salario del CEO	67.6%
Permanencia del CEO	29.2yrs
Participación del CEO	4.8%
Permanencia media de la dirección	1.5yrs
Promedio de permanencia en la Junta Directiva	4.5yrs

Actualizaciones recientes de la dirección

Recent updates

Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

May 01

Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

Dec 29

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Aug 28

Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Jun 03

Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Apr 06

Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

Jan 10

With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case

Aug 16

Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18

Jun 27

Simcere Pharmaceutical Group Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Mar 27

Should You Be Adding Simcere Pharmaceutical Group (HKG:2096) To Your Watchlist Today?

Mar 21

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jinsheng Ren en comparación con los beneficios de Simcere Pharmaceutical Group?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	CN¥7m	CN¥5m	CN¥715m
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥3b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	CN¥3m	CN¥2m	CN¥931m
Sep 30 2022	n/a	n/a	CN¥972m
Jun 30 2022	n/a	n/a	CN¥1b
Mar 31 2022	n/a	n/a	CN¥1b
Dec 31 2021	CN¥2m	CN¥2m	CN¥2b
Sep 30 2021	n/a	n/a	CN¥1b
Jun 30 2021	n/a	n/a	CN¥1b
Mar 31 2021	n/a	n/a	CN¥856m
Dec 31 2020	CN¥2m	CN¥1m	CN¥670m
Sep 30 2020	n/a	n/a	CN¥699m
Jun 30 2020	n/a	n/a	CN¥728m
Mar 31 2020	n/a	n/a	CN¥866m
Dec 31 2019	CN¥2m	CN¥1m	CN¥1b

Compensación vs. Mercado: La compensación total de Jinsheng($USD1.03M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD538.18K).

Compensación vs. Ingresos: La compensación de Jinsheng ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Jinsheng Ren (61 yo)

29.2yrs

Permanencia

CN¥7,426,000

Compensación

Mr. Jinsheng Ren founded Simcere Pharmaceutical Group Limited in March 1995 and its Chairman since 2023 and serves as its Director and also serves as its Chief Executive Officer since November 19, 2019 an...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jinsheng Ren	Co-Founder	29.2yrs	CN¥7.43m	4.84% CN¥ 708.1m
Yushan Wan	CFO, Joint Company Secretary & Executive Director	4.5yrs	CN¥9.36m	0.048% CN¥ 7.0m
Renhong Tang	Executive Director	1.3yrs	CN¥14.53m	0.060% CN¥ 8.8m
Xi Wang	VP & Executive Director	1.3yrs	CN¥1.33m	sin datos
Gaobo Zhou	Chief Investment Officer	1.3yrs	sin datos	sin datos
Quanfu Feng	Vice President of Marketing	no data	sin datos	sin datos
Tong Zhu	Chief Operating Officer of Simcere Zaiming	2.1yrs	sin datos	sin datos
Tamas Oravecz	Senior VP & Chief Scientific Officer of U.S.	1.7yrs	sin datos	sin datos
Aik Han Goh	Senior VP & Chief Medical Officer	less than a year	sin datos	sin datos
Wang John	Senior Vice President	less than a year	sin datos	sin datos
Po Man Mak	Joint Company Secretary	3.7yrs	sin datos	sin datos

1.5yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2096 no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jinsheng Ren	Co-Founder	8.5yrs	CN¥7.43m	4.84% CN¥ 708.1m
Yushan Wan	CFO, Joint Company Secretary & Executive Director	4.5yrs	CN¥9.36m	0.048% CN¥ 7.0m
Renhong Tang	Executive Director	4.5yrs	CN¥14.53m	0.060% CN¥ 8.8m
Xi Wang	VP & Executive Director	1.3yrs	CN¥1.33m	sin datos
Jianguo Wang	Independent Non-Executive Director	4.5yrs	CN¥360.00k	sin datos
Xinhua Wang	Independent Non-Executive Director	4.5yrs	CN¥360.00k	sin datos
Ruilin Song	Independent Non-Executive Director	4.5yrs	CN¥360.00k	sin datos
Ka Woon Sung	Independent Non-Executive Director	1.3yrs	CN¥360.00k	sin datos

4.5yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de 2096 se considera experimentada (4.4 años de antigüedad promedio).

Simcere Pharmaceutical Group Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024

Co-Founder recently bought HK$1.2m worth of stock

Co-Founder recently sold HK$710k worth of stock

Co-Founder recently sold HK$2.3m worth of stock

Co-Founder recently bought HK$1.5m worth of stock

Co-Founder recently sold HK$3.1m worth of stock

Recent updates

Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 14%

Dividend of CN¥0.16 announced

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024

Consensus EPS estimates fall by 37%

Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500

Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023

Consensus EPS estimates fall by 35%

Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets

Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

Simcere Pharmaceutical Group Limited Announces Localization Application of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug for SIM0501 (An Usp1 Small-Molecule Inhibitor) Issued by U.S. Food and Drug Administration

Simcere Pharmaceutical Group Limited and Neurodawn Pharmaceutical Co., Ltd. Obtains Clinical Trial Approval Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration

Co-Founder recently bought HK$1.2m worth of stock

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Consensus revenue estimates fall by 22%

First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022)

Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Co-Founder recently sold HK$710k worth of stock

New minor risk - Insider selling

Co-Founder recently sold HK$2.3m worth of stock

Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023

Co-Founder recently bought HK$1.5m worth of stock

Upcoming dividend of CN¥0.16 per share at 2.3% yield

Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Co-Founder recently sold HK$3.1m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Consensus revenue estimates fall by 13%

Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Now 23% undervalued

Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director

Investor sentiment deteriorated over the past week

Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration

Now 24% undervalued

Co-Founder recently bought HK$7.9m worth of stock

Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

Simcere Pharmaceutical Group Limited Appoints Mr. Tang Renhong as the Chairman of the Board of Directors and Chief Executive Officer of Simcere Zaiming Pharmaceutical Co., Ltd., with Effect from January 1, 2023

Simcere Pharmaceutical Group Limited Announces - the Clinical Trial Approval for SIM0348 Injection (Humanized TIGIT/PVRIG Bispecific Antibody) Issued by the National Medical Products Administration

Now 20% undervalued

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Announces Phase II/III Clinical Trial of Its 3Cl-Targeting anti-SARS-CoV-2 Drug Candidate Complete All Patients Enrollment

Simcere Pharmaceutical Group Limited Announces A Phase II/III Clinical Study of Anti-Sars-COV-2 Drug Candidate XIANNUOXIN (SIM0417) Complete All Patients Enrollment

Investor sentiment deteriorated over the past week

Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind, Parallel and Placebo-Controlled Phase III Clinical Study

Insufficient new directors

Simcere Pharmaceutical Group Limited Announces Executive Changes

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug Application

Investor sentiment improved over the past week

First half 2022 earnings released: EPS: CN¥0.024 (vs CN¥0.21 in 1H 2021)

Consensus EPS estimates fall by 20%

Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP

Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP

First half 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.21 in 1H 2021)

Simcere Pharmaceutical Group Limited Announces Executive and Committee Changes

Simcere Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 31, 2022